Live from the NIH registry
Studies recruiting near Hickory right now
Top 25 of 95 recruiting studies, sorted by proximity — each links to its official registry page
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
Viral Respiratory Infection, Viral Respiratory Illnesses
Phase 2
Interventional 1,100 participants sought
Accellacare of Piedmont HealthCare — Statesville, North Carolina (24.6 mi)
· Sponsor: ENA Respiratory Pty Ltd
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
Uncontrolled Gout
Phase 3
Interventional 270 participants sought
Research Carolina Elite — Denver, North Carolina (21.9 mi)
· Sponsor: Amgen
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Phase 1, Phase 2
Interventional 92 participants sought
Wake Forest Baptist Health - Wilkes Medical Center — Wilkesboro, North Carolina (29.4 mi)
· Sponsor: National Cancer Institute (NCI)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Phase 3
Interventional 942 participants sought
Advanced Respiratory and Sleep Medicine - Hickory- Site Number : 8400013 — Hickory, North Carolina (1.2 mi)
· Sponsor: Sanofi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Novant Health Cancer Institute - Statesville — Statesville, North Carolina (24.6 mi)
· Sponsor: SWOG Cancer Research Network
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Colorectal Cancer, Sarcopenia
N/A
Observational 300 participants sought
Wake Forest Baptist Health - Wilkes Medical Center — Wilkesboro, North Carolina (29.4 mi)
· Sponsor: Wake Forest University Health Sciences
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NASH With Fibrosis, MASH With Fibrosis
Phase 3
Interventional 1,650 participants sought
Akero Clinical Study Site — Statesville, North Carolina (24.6 mi)
· Sponsor: Akero Therapeutics, Inc
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Obesity or Overweight, Weight-Related Comorbidity
Phase 3
Interventional 500 participants sought
Research Site — Statesville, North Carolina (24.6 mi)
· Sponsor: AstraZeneca
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Narcolepsy Type 1, Narcolepsy Type 2
Phase 2
Interventional 90 participants sought
Denver, North Carolina — Denver, North Carolina (21.9 mi)
· Sponsor: Centessa Pharmaceuticals (UK) Limited
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Graves Disease
Phase 3
Interventional 300 participants sought
Site-033 — Statesville, North Carolina (24.6 mi)
· Sponsor: Biohaven Therapeutics Ltd.
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Phase 3
Interventional 2,500 participants sought
Anthos Investigative Site 1001 — Lenoir, North Carolina (17.0 mi)
· Sponsor: Anthos Therapeutics, Inc.
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Macular Degeneration, Age-Related Macular Degeneration
Phase 2, Phase 3
Interventional 960 participants sought
Graystone Eye — Hickory, North Carolina (1.2 mi)
· Sponsor: EyeBiotech Ltd.
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 2
Interventional 112 participants sought
Wake Forest Baptist Health - Hematology Oncology - Statesville — Statesville, North Carolina (24.6 mi)
· Sponsor: SWOG Cancer Research Network
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1, Narcolepsy Type 2
Phase 2, Phase 3
Interventional 222 participants sought
Denver, North Carolina — Denver, North Carolina (21.9 mi)
· Sponsor: Centessa Pharmaceuticals (UK) Limited
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Phase 2, Phase 3
Interventional 992 participants sought
Atrium Health Lincoln/LCI-Lincolnton — Lincolnton, North Carolina (18.9 mi)
· Sponsor: National Cancer Institute (NCI)
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Breast Cancer, NOS, CNS Primary Tumor, NOS
N/A
Interventional 400 participants sought
CaroMont Health - Lincoln Cancer Center — Lincolnton, North Carolina (18.9 mi)
· Sponsor: Eastern Cooperative Oncology Group
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
Phase 3
Interventional 752 participants sought
IMA Clinical Research PC 3 — Hickory, North Carolina (1.2 mi)
· Sponsor: Janssen Research & Development, LLC
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Chronic Kidney Disease
Phase 3
Interventional 7,000 participants sought
Research Site — Statesville, North Carolina (24.6 mi)
· Sponsor: AstraZeneca
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular Disease, Overweight
Phase 3
Interventional 12,800 participants sought
Burke Primary Care Family Practice — Morganton, North Carolina (20.3 mi)
· Sponsor: Amgen
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Obesity, Type 2 Diabetes
Phase 3
Interventional 2,500 participants sought
Piedmont Healthcare/Research — Statesville, North Carolina (24.6 mi)
· Sponsor: Novo Nordisk A/S
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Obesity, Overweight
Phase 1
Interventional 114 participants sought
PHC Accelacare — Statesville, North Carolina (24.6 mi)
· Sponsor: Novo Nordisk A/S
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Phase 3
Interventional 280 participants sought
Local Institution - 176 — Hickory, North Carolina (1.2 mi)
· Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
Narcolepsy
Phase 2
Interventional 64 participants sought
Research Carolina Elite — Denver, North Carolina (21.9 mi)
· Sponsor: Eisai Inc.
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
COPD, Chronic Obstructive Pulmonary Disease
N/A
Interventional 200 participants sought
Wake Forest School of Medicine — Salem, North Carolina (21.2 mi)
· Sponsor: Nuvaira, Inc.
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 1,524 participants sought
Novant Health Cancer Institute - Statesville — Statesville, North Carolina (24.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology